Mucormycosis at a tertiary-care center in Mexico. A 35-year retrospective study of 214 cases
- PMID: 33253454
- DOI: 10.1111/myc.13222
Mucormycosis at a tertiary-care center in Mexico. A 35-year retrospective study of 214 cases
Abstract
Background: Mucormycosis is a rare, invasive disease associated with high mortality rates, produced by opportunistic pathogens related to the Mucorales order and characterised by a diverse range of clinical forms; acute rhino-orbital-cerebral and pulmonary symptoms are the most reported ones.
Objectives: To report the experience of mucormycosis observed in a tertiary-care hospital in Mexico for 35 years.
Methods: This was a retrospective, descriptive and observational study on mucormycosis at a tertiary-care hospital in Mexico from January 1985 to December 2019. Demographic and clinical data and mycological and histopathological records were selected.
Results: Two hundred fourteen proven cases of mucormycosis for 35 years at a tertiary-care hospital in Mexico were included. Most of the cases were male patients with a median age of 45 years. The two most associated underlying diseases were diabetes mellitus (76.6%) and haematologic malignancy (15.4%). The three primary clinical forms were as follows: rhino-orbito-cerebral (75.9%), cutaneous (8.41%) and pulmonary (7.47%) mucormycosis. The most isolated agents were Rhizopus arrhizus (58.4%) and Lichtheimia corymbifera (12.3%). The overall therapeutic response was 58.5%, and the best response was observed with amphotericin B deoxycholate and surgical debridement.
Conclusion: Mucormycosis is an emerging disease, and its incidence has increased at our hospital over the years. In this study, the rhino-cerebral clinical type was the most frequent in patients with uncontrolled diabetes; the main aetiological agent was R. arrhizus. Early diagnosis, control of the underlying disease and prompt management may increase the survival rate.
Keywords: Mucorales; Rhizopus arrhizus; Mucormycosis; amphotericin B; diabetes; neutropenia; surgical debridement.
© 2020 Wiley-VCH GmbH.
Similar articles
-
Mucormycosis with cutaneous involvement. A retrospective study of 115 cases at a tertiary care hospital in Mexico.Australas J Dermatol. 2021 May;62(2):162-167. doi: 10.1111/ajd.13508. Epub 2020 Nov 22. Australas J Dermatol. 2021. PMID: 33222179
-
A prospective study of mucormycosis in north India: experience from a tertiary care hospital.Med Mycol. 2015 Apr;53(3):248-57. doi: 10.1093/mmy/myu086. Epub 2015 Jan 13. Med Mycol. 2015. PMID: 25587084
-
Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases.Med Mycol. 2018 Jan 1;56(1):29-43. doi: 10.1093/mmy/myx017. Med Mycol. 2018. PMID: 28431008
-
Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.Ann Pharmacother. 2016 Sep;50(9):747-57. doi: 10.1177/1060028016655425. Epub 2016 Jun 15. Ann Pharmacother. 2016. PMID: 27307416 Review.
-
Paediatric cutaneous mucormycosis: A case report and review of the literature.Mycoses. 2022 Jul;65(7):674-682. doi: 10.1111/myc.13452. Epub 2022 May 24. Mycoses. 2022. PMID: 35514044 Review.
Cited by
-
Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis.J Fungi (Basel). 2022 Apr 25;8(5):445. doi: 10.3390/jof8050445. J Fungi (Basel). 2022. PMID: 35628701 Free PMC article. Review.
-
Deoxycholate amphotericin for management of mucormycosis: a retrospective cohort study from South India.Infez Med. 2022 Sep 1;30(3):432-439. doi: 10.53854/liim-3003-12. eCollection 2022. Infez Med. 2022. PMID: 36148169 Free PMC article.
-
Antifungal stewardship: the Latin American experience.Antimicrob Steward Healthc Epidemiol. 2023 Dec 5;3(1):e217. doi: 10.1017/ash.2023.471. eCollection 2023. Antimicrob Steward Healthc Epidemiol. 2023. PMID: 38156226 Free PMC article. Review.
-
Mucormycosis in Indian COVID-19 Patients: Insight into Its Patho-Genesis, Clinical Manifestation, and Management Strategies.Antibiotics (Basel). 2021 Sep 6;10(9):1079. doi: 10.3390/antibiotics10091079. Antibiotics (Basel). 2021. PMID: 34572661 Free PMC article. Review.
-
Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States.J Clin Microbiol. 2021 Aug 18;59(9):e0123021. doi: 10.1128/JCM.01230-21. Epub 2021 Aug 18. J Clin Microbiol. 2021. PMID: 34232068 Free PMC article.
References
REFERENCES
-
- Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006;25:215-229.
-
- Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin Microbiol Infect. 2009;15(suppl. 5):10-14.
-
- Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653.
-
- Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421.
-
- Spatafora JW, Chang Y, Benny GL, et al. A phylum-level phylogenetic classification of zygomycete fungi based on genome-scale data. Mycologia. 2016;108:1028-1046.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources